Variability of Patterns of Fatigue and Quality of Life Over Time Based on Different Breast Cancer Adjuvant Chemotherapy Regimens

Ann M. Berger, PhD, RN, AOCN®, FAAN, Kari Lockhart, MSN, APRN, and Sangeeta Agrawal, MSc

Breast cancer is the most frequently diagnosed cancer among women in the United States. According to the American Cancer Society ([ACS], 2009), an estimated 192,370 new cases of invasive breast cancer and an additional 62,280 new cases of in situ breast cancer are expected to occur in the United States in 2009. Since 1990, deaths from breast cancer in women younger than age 50 have decreased by 3.3% per year, and in women age 50 or older, by 2% per year (ACS, 2009). With a decrease in death rates has come an increase in five-year survival rates. The five-year survival rate is 98% for localized disease and 84% for regional breast cancer (ACS, 2009). This adds up to more than 2.3 million breast cancer survivors in the United States today (ACS, 2007).

Adjuvant chemotherapy usually is recommended after surgery for patients who are at significant risk for disseminated disease. Chemotherapy has been demonstrated to reduce the risk of breast cancer recurrence by 30%–50% (Moulder & Hortobagyi, 2008). Anthracycline-based regimens, including doxorubicin or epirubicin, are the breast cancer adjuvant chemotherapy standards of care (National Comprehensive Cancer Network [NCCN], 2008b). Medical oncologists perform a thorough workup to determine prognostic information to select one chemotherapy regimen over another. One of the newer laboratory tests that has been found to help determine which type of chemotherapy will be superior to another is the level of human epidermal growth factor receptor 2 (HER2-neu) expression (NCCN, 2008b). Lymph node status also helps oncologists decide whether to add taxanes (i.e., paclitaxel or docetaxel) to the chemotherapy regimen (Box & Russel, 2004). Clinical trials have found improved disease-free and overall survival rates for lymph node-positive breast cancer by adding taxanes after standard anthracycline-based chemotherapy treatments and by delivery of identical doses of chemotherapy on a more frequent basis, referred to as dose-dense therapy (Moulder & Hortobagyi).

Cancer-related fatigue (CRF) is the most common complaint of patients (Prue, Rankin, Allen, Gracey, & Cramp, 2006). Fatigue has been reported by more than 90% of patients with cancer (Prue et al.). Factors that have been related to increased levels of CRF in patients include anxiety, depression, anemia, poor sleep quality, symptom distress, and lower levels of physical activity (de Jong, Courtenz, Abu-Saad, & Schouten, 2002; Prue et al.). Evidence-based interventions for CRF have been rated for their effectiveness by the Oncology Nursing Society (de Jong, Courtens, Abu-Saad, & Schouten, 2002; Prue et al.). Evidence-based interventions for CRF have been rated for their effectiveness by the Oncology Nursing Society.